| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Friday, July 01, 2016 9:57:53 AM
@twi...
Quoting you: "no one except
a few dozen readers of this message board
is anticipating an interim stop.
the unexpected good news will be, no futility stop,
while the market has priced one in."
Hopefully you are including me (excuse me..can not help it)
" We few. We precious few. We band of brothers"
Henry V...W. Shakespeare
While I am a fan of "abridged notes", I believe you are pushing the envelope here. Two points...There has been a land-swell of positive information recently supporting n-3s as having beneficial effects on CVD risk..Anyone betting big money on this binary event would have to be brave indeed to imagine results bad enough to halt for futility..The other point is that trials halted for futility at interim usually are halted not because the drug is useless, but rather the drug is dangerous. If there were serious AEs (non CVD adverse events)) we would know about them already, as these AEs are unblinded to the sponsor and FDA.
Indeed futility would fly in the face not only of JELIS, but that of Japan itself and Greenland and the Eskimos. It would counterfeit the eicosanoid system and suggest there was some cryptic metabolic system that has thus far evaded all scientific and medical radar...And believe me discovering the eicosanoid system was one of the greatest scientific detective stories...
I wish there would be an up sweep of the PPS if not halted, but I think we will see the PPS back at these levels...
JMO..Regards...@JL
Quoting you: "no one except
a few dozen readers of this message board
is anticipating an interim stop.
the unexpected good news will be, no futility stop,
while the market has priced one in."
Hopefully you are including me (excuse me..can not help it)
" We few. We precious few. We band of brothers"
Henry V...W. Shakespeare
While I am a fan of "abridged notes", I believe you are pushing the envelope here. Two points...There has been a land-swell of positive information recently supporting n-3s as having beneficial effects on CVD risk..Anyone betting big money on this binary event would have to be brave indeed to imagine results bad enough to halt for futility..The other point is that trials halted for futility at interim usually are halted not because the drug is useless, but rather the drug is dangerous. If there were serious AEs (non CVD adverse events)) we would know about them already, as these AEs are unblinded to the sponsor and FDA.
Indeed futility would fly in the face not only of JELIS, but that of Japan itself and Greenland and the Eskimos. It would counterfeit the eicosanoid system and suggest there was some cryptic metabolic system that has thus far evaded all scientific and medical radar...And believe me discovering the eicosanoid system was one of the greatest scientific detective stories...
I wish there would be an up sweep of the PPS if not halted, but I think we will see the PPS back at these levels...
JMO..Regards...@JL
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
